571 results about "Sulfation" patented technology

Hyaluronic acid, hyaluronate esters and salts thereof are sulfated such that the number of sulfate groups per monomeric unit is in the range of from 0.5 to 3.5. The sulfated derivatives exhibit anticoagulant and cell adhesion reduction properties, and may be used to prepare biomaterials.

The present invention relates to specific compositions made by the sulfation of alkoxylated crude guerbet alcohol mixtures that contain between 15% and 50% lower molecular weight alkoxylated alcohols. The lower molecular weight alcohols are the raw material alcohols used to make the guerbet. Sulfated compositions made from this specific bi-modal distribution have unique emulsification properties and experience minimal chromatographic separation when used in downhole applications.

Branched, substantially unsaturated fatty alcohol sulfates are produced by a process which comprises the steps of: (a) dimerizing unsaturated C16-22 fatty acid to form a dimer fraction and a monomer fraction comprised of branched, substantially unsaturated fatty acids and straight chain saturated fatty acids, (b) removing the monomer fraction from the dimerization step, (c) converting the branched, substantially unsaturated fatty acids from step (b) into the corresponding fatty acid methyl esters, (d) hydrogenating the branched, substantially unsaturated fatty acid methyl esters with the double bonds intact to form the corresponding branched, substantially unsaturated fatty alcohols and (e) sulfating and neutralizing the branched, substantially unsaturated fatty alcohols. The fatty alcohol sulfates thus produced exhibit improved performance properties and greater oxidative stability than standard unsaturated fatty alcohol sulfates.

PCT No. PCT/EP97/02379 Sec. 371 Date Nov. 6, 1998 Sec. 102(e) Date Nov. 6, 1998 PCT Filed May 9, 1997 PCT Pub. No. WO97/43317 PCT Pub. Date Nov. 20, 1997Derivatives of the K5 polysaccharide having anticoagulant activity higher than heparin, obtained by a process including the steps of reacting: with an organic base a solution of K5 polysaccharide N-deacetylated, N-sulfated and epimerized at least to an iduronic acid content of 50% treating with a sulfating agent to obtain the N-resulfation of the possible N-desulfated groups.

The invention provides a lead-carbon battery negative pole preparation method based on a ZIF-8 zeoliteimidazate framework porous carbon nanomaterial and belongs to the technical field of lead-carbon battery negative polematerials. The ZIF-8 zeoliteimidazate framework porous carbon nanomaterial is a porous carbon material prepared by conducting annealing on a metal organic framework material synthesized by using zinc as metal ions and using 2-methyl imidazole as an organic ligand under protective atmosphere. Lead and the ZIF-8 zeoliteimidazate framework porous carbon nanomaterial are grinded and mixed in a ball mill. A lead-carbon battery can effectively inhibit irreversible sulfation occurred on a negative pole plate during charging and discharging and has superior high rate capability and excellent cycle performance. A negative pole can be used for large commercial energy storage lead-carbon batteries.

Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biochemicals from the activated mast cells, the compositions containg one or more of a flavone or flavonoid glycoside a heavily sulfated, non-bovine proteoglycan, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, a hexosamine sulfate such as D-glucosamine sulfate, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, a long-chain unsaturated fatty acid, a phospholipid, Krill oil, a polyamine, glutiramer acetate and interferon. Certain of the present compositions are useful in protecting against the neuropathological components of multiple sclerosis and similar inflammatory neurological diseases.

Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of active Tumor Necrosis Factor Alpha (TNF- alpha ) can be either inhibited or augmented selectively by administration to the host of an effective amount of a substance of the invention. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF- alpha . The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be administered daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of up to about 5-8 days, preferably once a week.

Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, an unrefined olive kernel oil/extract that increases absorption of these compositions in various routes of administration, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.

The invention is a solid strong-acid catalyst, containing a mixed oxide sulfated by sulfocompound, its sulfur content 1.0-2.5 m%, where the mixed oxide is composed of zirconia, silicon oxide and alumina in the dry-based mass ratio of 30-90 to 1-30 to 9-40, and the monoclinic crystal phase proportion of zirconia is 10-70 m% and the rest square crystal phases. It is applied to isomerization reaciton of C4-C7 alkanes and has higher isomerization activity and selectivity.

The invention discloses a super lead carbon battery with an active carbon negative electrode and a preparation method thereof. The negative electrode of the supper lead carbon battery comprises the active carbon negative electrode and a lead negative electrode which are internally parallel. A positive electrode of the battery adopts PbO2 as an active substance. A separator adopts an AGM diaphragm. Electrolyte adopts 1.0-1.4g/cm<3> sulfuric acid. By introducing the active carbon negative electrode into the lead negative electrode in parallel internally to act as the active substance, the invention can greatly promote the charge acceptance ability of the negative electrode, effectively improve the low temperature property of the super lead carbon battery, and greatly mitigate sulfation phenomenon in the negative electrode, so that the deep-cycle life can reach more than 1,800 times. Compared with cost of an inorganic system carbon-carbon symmetric mode and a nickel electrode-carbon mixed alkali system, the invention can greatly reduce the material cost of products. Compared with a traditional lead-acid battery, the invention can greatly prolong recycling lifetime of products and have obvious performance price ratio advantage.

Quaternary ammonium, betaine, or sulfobetaine compositions derived from fatty amines, wherein the fatty amine is made by reducing the amide reaction product of a metathesis-derived C₁₀-C₁₇ monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives and a secondary amine, are disclosed. Quaternary ammonium, betaine, or sulfobetaine compositions derived from fatty amidoamines, wherein the amidoamine is made by reacting of a metathesis-derived C₁₀-C₁₇ monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives and an aminoalkyl-substituted tertiary amine, are also disclosed. The quaternized compositions are advantageously sulfonated or sulfated. In one aspect, the ester derivative of the C₁₀-C₁₇ monoun-saturated acid or octadecene-1,18-dioic acid is a lower alkyl ester. In other aspects, the ester derivative is a modified triglyceride made by self-metathesis of a natural oil or an unsaturated triglyceride made by cross-metathesis of a natural oil with an olefin. The quaternary ammonium, betaine, and sulfobetaine compositions and their sulfonated or sulfated derivatives are valuable for a wide variety of end uses, including cleaners, fabric treatment, hair conditioning, personal care (liquid cleansing products, conditioning bars, oral care products), antimicrobial compositions, agricultural uses, and oil field applications.

Procedure for the synthesis of deprotected pentasaccharides from a protected precursor pentasaccharide through a reaction procedure having five stages whereamong is included an N-sulphation of amino groups and a hydrogenolysis of benzyl groups. Through this procedure a drastic reduction is achieved in the total synthesis time in comparison with the process traditionally employed, together with increased reproducibility thereof, permitting the standardisation thereof.

The present invention provides antibodies that bind an epitope of PSGL-1 comprising the motif D-X-Y-D, wherein X represents any amino acid or the covalent linkage between D and Y, and Y is sulfated, which antibody can be complexed with one or more copies of an agent. The antibodies of the invention can be used in a method of inducing antibody-dependent cell cytotoxicity and/or stimulating natural killer (NK) cells or T cells. In addition, by administering these antibodies to a patient in need thereof, a method of inducing cell death is provided. A method of preventing infection by a virus (e.g., HIV) by administering to a patient in need thereof an antibody of the present invention is also provided. The, present invention also provides a method of introducing an agent into a cell that expresses sulfated PSGL-1 by coupling or complexing an agent to an antibody of the present invention and administering the complex to the cell. Finally, the present invention provides methods of diagnosis, prognosis and staging using the present antibodies.

The invention discloses a negative plate of a lead-carbon battery and a preparation method thereof. The negative plate consists of lead powder, active carbon, carbon black, barium sulfate, sodium lignosulfonate, humic acid, short fiber and sulfuric acid. The battery prepared by the negative plate has the advantages that the charging acceptance can be effectively improved, the sulfation phenomenon of the negative electrode under high-rate partial state of charge (HRPSoC) is effectively relieved, the times of 2C charge-discharge rate circulation (3%DOD) under 50% state of charge can reach 18442, and compared with the traditional lead-acid storage battery, the cycle life can be prolonged by more than two times.

Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, an unrefined olive kernel oil/extract that increases absorption of these compositions in various routes of administration, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.

The present invention provides methods, processes and reaction mixtures, which produce sulfated heparosan polysaccharides. This invention also provides methods and reaction mixtures for the synthesis of N-deacetylate N-sulfate derivatives of non-sulfated N-acetyl heparosan (HS) polysaccharides.

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear steroid metabolite that increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides (e.g. hypercholesterolemia, hyperlipidemia, and atherosclerosis) are also provided.

The invention relates to the field of recombinant DNA technology for the production of chondroitin, including the production of chondroitin sulfate via a combination of recombinant bacterial fermentation and post-fermentation sulfation.